Compare FTAI Aviation Ltd (FTAI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Twist Bioscience Corp — how do they compare? FTAI Aviation Ltd trades at $171 (market cap $17.57B), while Twist Bioscience Corp trades at $155.24 (market cap $10.08B). The key difference: FTAI Aviation Ltd is the larger of the two by market cap, and FTAI Aviation Ltd pays a 1.17% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 22 Days and Twist Bioscience Corp for 27 Days on average.
| FTAI | TWST | |
|---|---|---|
Market Cap | $17.57B | $10.08B |
Volume | 1,905,014 | 4,229,037 |
Sector | Industrials | Health |
52-Week High | $310.04 | $205.00 |
52-Week Low | $152.80 | $25.45 |
Typical Hold Time | 22 Days | 27 Days |
Enterprise Value | $20.69B | $10.01B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $174.83, down 2.57% with a bearish technical signal despite unanimous analyst buy ratings. The company reported strong revenue growth to $2.51B in 2025 but missed Q2 2026 EPS estimates. Recent developments include a $500M share repurchase program and acquisition of 27 Boeing 737-700 aircraft, signaling strategic expansion in aerospace services.
FTAI presents a compelling growth story with 100% analyst buy consensus and $321.25 price target, but faces execution risks from negative operating cash flow and earnings misses. The transition to fee-based management and aerospace expansion offers upside potential, though high valuation multiples and cash flow concerns warrant caution.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
